tbuckley/cabot-search huggingface dataset:
Pomalidomide (POM) + low-dose dexamethasone (LoDEX) after lenalidomide (LEN)-based second-line (2L) treatment (Tx) in patients (Pts) with relapsed/refractory multiple myeloma (RRMM): Analysis of progression-free survival (PFS) by level of disease control.
Authors: David Siegel, Gary J. Schiller, Kevin W. Song, Richy Agajanian, Keith Stockerl-Goldstein, Hakan Kaya, Michael Sebag, Frederic J. Reu, Ehsan Malek, Giampaolo Talamo, Jorge L Mouro, Weiyuan Chung, Shankar Srinivasan, Max Qian, Syed Rizvi, Anjan Thakurta, Nizar J. Bahlis
Journal: Journal of Clinical Oncology (2017)

8027 Background: Recent trials of triple therapy in 2L and third-line (3L) Tx excluded pts refractory to LEN. This is not reflective of standard of care in first line and 2L where LEN is given until progressive disease (PD). MM-014 enrolled pts with RRMM and 2L LEN-based Tx failure. Here we report results only from cohort A of pts receiving POM + LoDEX. Cohort B will investigate POM + LoDEX + daratumumab. Methods: Adult pts with MM, 2 prior Tx lines, and PD after ≥ 2 cycles of 2L LEN-based Tx received POM + LoDEX. The primary endpoint was overall response rate (ORR). Other endpoints included time to response (TTR), PFS, second primary malignancies (SPMs), and biomarkers. Results: Of 51 pts in cohort A, 39 (76.5%) discontinued Tx. Most pts (88.2%) were refractory to their last LEN Tx, (median Tx duration 24.6 mos) and 72.5% had prior bortezomib. At a median follow-up of 13.6 mos, ORR was 29.4% (2.0% complete response, 9.8% very good partial response, and 17.6% partial response [PR]) and median TTR was 1.9 mos; 66% of pts had ongoing response at 1 yr. Minimal response [MR] was reached in 15.7%. Median PFS was 13.8 mos. Pts with ≥ MR had similar Tx durations as those achieving ≥ PR. Additional results in Table. Post-Tx T-cell populations were significantly higher vs baseline (CD3 + , 72.6% vs 67.8%; CD3 + /CD8 + , 36.9% vs 32.1%). Relative changes from baseline were significantly greater in pts with response vs pts with no response (CD3 + , 10.4 vs −0.8; CD3 + /CD4 + , 4.2 vs −3.5). Conclusions: This update confirms the safety and efficacy of POM + LoDEX following 2L LEN-based Tx failure in pts with RRMM. Hematologic adverse event (AE) rates improved and median PFS was longer with 3L use than previously reported with POM + LoDEX use in later Tx lines. In addition, achieving disease control of ≥ MR led to similar PFS rates as reaching ≥ PR. Clinical trial information: NCT01946477. [Table: see text]
Endothelial dysfunction in adult survivors of childhood cancer: A report from the St. Jude Lifetime Cohort study.
Authors: Daniel A. Mulrooney, Kirsten K. Ness, Sujuan Huang, Aimee Santucci, Robert P. Hebbel, Anna S. Solovey, Daniel Duprez, Matthew J. Ehrhardt, Daniel M. Green, Deokumar Srivastava, Leslie L. Robison, Melissa M. Hudson
Journal: Journal of Clinical Oncology (2017)

10564 Background: Endothelial dysfunction, as an indicator of vascular disease in childhood cancer survivors (CCS) has not been widely studied. Methods: Markers of vascular inflammation (high sensitivity C-reactive protein [hsCRP]), hemostasis (fibrinogen), activation (endothelial cell expression of vascular cell adhesion molecule [VCAM-1]) and functional testing (large/small artery elasticity [L/SAE], pulse wave velocity [PWV]) were assessed in 200 CCS, ≥10 years from diagnosis, and 192 age/gender matched healthy controls. Exclusion criteria included: inflammatory processes, use of anti-inflammatory or cardiovascular medications, or pregnancy. Differences were assessed by adjusted multivariable linear regression. Results: CCS (53% male) of leukemia/lymphoma (59%), central nervous system tumors (6%), sarcomas (11.5%), embryonal tumors (22.5%), and other (1%) had a mean age at diagnosis 7.3 years (SD ±5.7). CCS and controls did not differ in current age (mean 34.1 ±9.2 vs. 33.5 years ±9.8), body mass index, smoking, mean systolic (124 mm Hg ±11.7 vs. 123 ±11.9) or diastolic blood pressure (73 ±9.5 vs. 71 ±9.5). Fasting low- (110 mg/dl ±31 vs. 102 ±30) and high-density (52 ±16 vs. 56 ±18) cholesterol levels differed between survivors and controls (p&lt;0.01). Endothelial expression of VCAM-1 and PWV were statistically significantly increased in CCS; arterial elasticity was significantly reduced (table). Therapeutic exposures (anthracyclines and radiation) were not significantly associated with endothelial dysfunction. Conclusions: Childhood cancer survivors have greater endothelial dysfunction, a sign of atherosclerosis, and preventive measures should be investigated. [Table: see text]
Everolimus in anaplastic thyroid cancer: A case series.
Authors: Ethan James Harris, Glenn J. Hanna, Nicole Grace Chau, Guilherme Rabinowits, Robert I. Haddad, Danielle Nina Margalit, Jonathan Daniel Schoenfeld, Roy B. Tishler, Justine A. Barletta, Matthew Nehs, Pasi A. Janne, Julian Huang, Phillip Groden, Alec Kacew, Jochen H. Lorch
Journal: Journal of Clinical Oncology (2018)

e18112 Background: Anaplastic thyroid cancer (ATC) accounts for 1-3% of all thyroid cancers. It is extremely aggressive and mortality remains high. No systemic standard of care exists for patients with metastatic disease. We report our off-protocol experience with the mTOR inhibitor, everolimus, in patients with incurable ATC. Methods: Patients with metastatic or incurable ATC treated off label with everolimus at the Dana-Farber Cancer Institute between 2013-2016 were identified. Sequencing of a panel with 447 tumor genes was performed in cases with sufficient material. Results: Five patients were identified. The cohort was composed of four males and one female with a median age at diagnosis of 75. Three patients had metastatic disease, and two patients had unresectable locoregional disease. Median follow-up was 7.4 months, and median survival was 9.3 months. One patient achieved a partial response lasting 27.9 months, and two patients had disease stability for 3.7 and 5.9 months, respectively. Sequencing data was available for two of the patients and revealed that the partial responder carried two mutations in PIK3CA and one in BRAF. Conclusions: It appears that everolimus has activity in ATC. Genetic analysis may be helpful to identify patients likely to respond.
Prognostic stratification using the nomogram sarculator and its impact on study results in a randomized controlled trial (RCT) for localized soft tissue sarcomas (STS): A secondary analysis of the EORTC-STBSG 62931.
Authors: Sandro Pasquali, Sara Pizzamiglio, Nathan Touati, Saskia Litiere, Sandrine Marreaud, Bernd Kasper, Hans Gelderblom, Silvia Stacchiotti, Paolo Verderio, Paolo Giovanni Casali, Penella Woll, Alessandro Gronchi
Journal: Journal of Clinical Oncology (2018)

11518 Background: To determine whether high-risk STS patients identified using individual patient data and the nomogram Sarculator, benefitted from adjuvant chemotherapy in a RCT which failed to detect any overall survival (OS) differences between chemotherapy and observation. Methods: Data from the EORTC 62931 RCT comparing adjuvant doxorubicin plus ifosfamide (Adj) and observation (Obs) for STS (Lancet Oncol 2012;13:1045-1054) were analysed. 10-yr predicted probability of OS (P-OS) was computed using a validated nomogram (Lancet Oncol 2016;17:671-80) for each participant with extremity and trunk wall STS (N = 290/351). Patients were divided in 3 categories of P-OS. OS and disease-free survival (DFS) were calculated at the study median follow-up (8-yr). Results: Nomogram P-OS were dispersed (median 72%, IQR 57-83%) and had prognostic value for OS and DFS (Log-Rank test: P < 0.001). Patients were grouped in 3 arbitrary P-OS categories: > 66% (high P-OS), > 51≤ 66 (intermediate P-OS), ≤ 51% (low P-OS). Most patients were in the high P-OS category (N = 170 [58.6%], 90 Obs/80 Adj), while 68 (23.5%, 34 Obs/34 Adj) and 52 (17.9%, 24 Obs/28 Adj) fell in the intermediate and low P-OS category, respectively. Adjuvant chemotherapy halved the risk of death in patients with low P-OS (HR = 0.46, 95%CI 0.23-0.94) with a 21.2% 8-yr absolute risk reduction (ARR) of death (8-yr OS: 42% and 21% for Adj and Obs, respectively). This effect was not detected in the intermediate (HR = 1.00, 95%CI 0.53-1.88) and high P-OS categories (HR = 1.08, 95%CI 0.61-1.90). There was a DFS benefit for chemotherapy in low P-OS (HR = 0.46, 95%CI 0.24-0.89) but not in the intermediate (HR = 0.74, 95%CI 0.41-1.34) and high P-OS (HR = 0.90, 95%CI 0.54-1.50) categories, leading to a 21% 8-yr ARR for adjuvant chemotherapy (8-yr DFS: 34% and 13% for Adj and Obs, respectively). Conclusions: In this RCT patients with a low predicted P-OS (i.e., high-risk patients) have a statistically significant higher OS and DFS when treated with the study doxorubicin-ifosfamide chemotherapy, although the analysis on all study patients was negative. Clinical trial information: NCT00002641.
Adjuvant therapy for gallbladder carcinoma (GBCA): Analysis of the National Cancer Data Base (NCDB).
Authors: Kalyan C. Mantripragada, Fatima Hamid, Adam J. Olszewski
Journal: Journal of Clinical Oncology (2016)

4082 Background: GBCA has a poor prognosis even when it is resectable. Guidelines recommend consideration of adjuvant chemoradiation (ACRT) or chemotherapy (ACH), but without high level evidence. Our objective was to evaluate ACH and ACRT in a nationwide GBCA dataset, while addressing potential sources of bias. Methods: We selected patients (pts) with T2-3N0 or T1-3N1-2 (N+) GBCA reported in 2004-2011 to the NCDB—an oncology registry capturing ~70% of cancers in the United States (US). We excluded pts managed without surgery, with grossly positive margins or medical contraindications to chemotherapy. We defined ACH/ACRT as treatment initiated within 3 months of surgery. We addressed missing data by multiple imputation, immortal time bias by landmark analysis (excluding pts with < 4 months of follow-up), and indication bias by propensity score analysis (inverse probability of treatment weighting, IPTW, and 1:1 matching). We verified balance of all available confounders, and assessed sensitivity to unobserved confounding. Overall survival (OS) was compared in Cox models reporting hazard ratio (HR) with 95% confidence intervals (CI). Results: Among 4,802 eligible pts, 1,384 (29%) received ACH (57% single-, 33% multi-agent, 10% unspecified), and 651 (14%) ACRT. ACH was less frequently applied in pts > 70 years old, Hispanic women, and pts with comorbidities. It was more common in T3 or N+ tumors, tumors > 5 cm in size, or with microscopically positive margins. Unadjusted 3-year (y) OS was 51% for T2, 26% for T3 and 31% for N+ GBCA. There was no evidence of improved OS after application of ACH (absolute OS difference at 3 y: 0.3%; IPTW estimate of HR = 1.00, CI, 0.92-1.10, matching estimate: HR = 0.98, CI, 0.88-1.08), and no evidence of heterogeneity by stage (P= .24). The effect of ACRT was heterogeneous, with significantly improved OS for T3 or N+ GBCA (OS difference at 3 y: 3.2%; IPTW HR = 0.83, CI, 0.73-0.95; matching HR = 0.84, CI, 0.72-0.99). Conclusions: Up to 2011, ACH was applied to a minority of GBCA pts in the US community, and without an evident OS advantage. ACRT modestly improved OS in T3 or N+ disease. Regimens with known superior activity in metastatic GBCA (cisplatin/gemcitabine) or novel approaches should be investigated.
Characterization and predictors of long term (≥ 10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer patients.
Authors: Michael Friedlander, John K. Chan, Jim Java, Deborah K Armstrong, Maurie Markman, Thomas J. Herzog, Bradley J. Monk, Floor Jenniskens Backes, Angeles Alvarez Secord, Albert J. Bonebrake, Peter Graham Rose, Krishnansu Sujata Tewari, Robert S. Mannel, Samuel S. Lentz, Melissa Ann Geller, Larry J. Copeland
Journal: Journal of Clinical Oncology (2018)

5556 Background: ~25% of patients with stage III OC are reported to be alive ≥ 10 years after diagnosis in registry studies1. Some have long term disease-free survival (LTDFS) without recurrence and others have recurrent active disease but the proportions of each is unclear. We propose to determine the proportion, characteristics, and predictors of long term survival in patients with stage III ovarian cancer (OC) enrolled in clinical trials who are ≥ 10 years LTDFS . Methods: Data from 3 NRG/GOG trials (104, 114, and 172) which enrolled patients to intraperitoneal (IP) vs. intravenous (IV) chemotherapy were analysed. Demographics and clinic-pathologic characteristics of patients living ≥ 10 years were tabulated. Using a landmark approach at 10 years, Cox regression survival analysis was performed to evaluate independent prognostic factors that predict LTDFS. Results: Of 1,229 stage III OC patients, 18.8% (232/1229) were alive ≥ 10 years. Of these, 13.7% (n = 168) had LTDFS ≥ 10 years and 5.2% (n = 64) had recurrent disease. Compared to the overall study group, the LTDFS ≥10 years patient had a median age of 54.8 vs. 57.2 years (p < 0.001), gross residual disease after primary surgery 42.3% vs. 45.8% (p = 0.027); serous cell type 62.5% vs. 68.4%; endometrioid 14.3% vs. 9.4% (p = 0.035), well differentiated cancers 12.5% vs. 8.5% (p < 0.001), respectively. Of the LTDFS patients, 45.2% were treated with IP and 54.8% with IV chemotherapy (p = 0.3). Age (HR = 1.077; 95% CI = 1.03–1.12; p < 0.001) was the only independent prognostic factor for LTDFS ≥10 years on multivariate Cox analysis. Conclusions: Approximately 14% of stage III ovarian cancer patients were in LTDFS at ≥10 years and an additional 5% were alive with recurrent disease. Younger age at diagnosis was the only independent prognostic factor for LTDFS ≥10 years. Further work is needed to understand characteristics and predictors of exceptional responders and whether they could be identified at initial diagnosis. 1 Baldwin et al Obstetrics & Gynecology: 2012: 120; 3: 612–618
Analytical validation of the Oncomine Immune Response Research Assay (OIRRA) in a CLIA and CAP regulated laboratory for formalin fixed, paraffin embedded (FFPE) solid tumor specimens.
Authors: John Williamson, Damion Whitfield, Harwinder Sidhu, Suzanne Salazar, Kristen Vandewalker
Journal: Journal of Clinical Oncology (2018)

e24200 Background: Immune-oncology has the potential to significantly advance our understanding of cancer biology. The ability to rapidly assess cancer-relevant gene expression (GEx) profiles using next generation sequencing (NGS) of FFPE specimens is a valuable tool to support this objective. OIRRA is a targeted, pan-cancer GEx assay designed to assess the expression of genes involved in tumor- immune interactions, with sample to result in 3 days. Here we describe an analytical validation of the OIRRA in a CAP/CLIA laboratory using a FFPE sample cohort. Methods: OIRRA was validated using a cohort of 50 FFPE samples. We characterized the limit- of-blank (LOB), amplicon performance, RNA input variation, accuracy and precision. FFPE were subjected to OIRRA testing using manual library preparation. FFPE libraries (30) and two controls were pooled, templated, and loaded onto an Ion 540 chip using the Ion Chef. Sequencing was performed on the Ion S5XL system, and data analyzed using Torrent Suite Software. For accuracy studies, NGS and qPCR GEx profiles were compared for a subset of target genes. OIRRA GEx profiles were compared using Spearman correlations. Results: Analysis of 50 FFPE specimens revealed 389/398 OIRRA target genes at greater than 20 reads per million demonstrating that each of these targets can be detected in a colorectal cancer enriched FFPE sample set. The correlation between OIRRA NGS profiles and qPCR profiles was 0.85. The LOB of the assay was determined by evaluating background readcounts in 70 no template control libraries and was 5 absolute reads per target. OIRRA profiles were obtained for a subset of FFPE cases with variable RNA input (0.625ng – 10ng), operator/day/instrument combinations, and intra-operator replicates to evaluate the precision of the assay. We observed a mean Spearman rho of > 0.98 indicating a strong correlation of GEx profiles across variables. Conclusions: Here we present the analytical validation of an Immune Oncology NGS panel in a CLIA/CAP regulated environment. We show robust performance in an FFPE sample set and demonstrate sufficient accuracy and precision for use in a clinical laboratory.
Abstract P172: Exercise Hemodynamics of Heart Failure with Preserved Ejection Fraction: a Meta-Analysis
Authors: Bryan Park, Rohan Khera, Ambarish Pandey, Mark Haykowsky, Dalane Kitzman, Jarett Berry
Journal: Circulation (2017)

Background: Heart failure with preserved ejection fraction (HFpEF) is associated with increased morbidity and mortality, and recalcitrant to available medical therapies. A major challenge in development of effective therapies for HFpEF is the heterogeneity in the underlying pathophysiological mechanisms, with numerous studies demonstrating conflicting findings. We conducted a meta-analysis to characterize the underlying exercise hemodynamic abnormalities that define HFpEF. Methods: 15 studies comparing hemodynamic parameters between HFpEF and normal or hypertensive controls were pooled. Standardized mean differences (SMD) in the exercise reserve (peak exercise - resting) measures of hemodynamic parameters between the HFpEF and control group were pooled using a random-effects model meta-analysis. Results: The meta-analysis included 627 HFpEF patients (age range: 57 - 74 years, 66% women, 80% with hypertension) and 365 normal controls (age range: 47 - 72 years, 58% women, 50% with hypertension). In pooled analysis, HFpEF patients had significantly lower peak oxygen uptake [SMD (95% CI): -1.8 (-1.9 to -1.6)]. HFpEF patients had significantly lower cardiac index (CI)[SMD (95% CI): -2.1 (-2.3 to -1.9)], heart rate (HR) [SMD (95% CI): -1.3 (-1.5 to -1.1)], stroke volume index (SVI)[SMD (95% CI): -0.78 (-0.94 to -0.61)] and arterio-venous oxygen difference (a-VO 2 Diff) reserve [SMD (95% CI): -0.68 (-0.91 to -0.44)]. HFpEF patients also had significantly greater increase in left ventricular filling (LV) pressure [SMD (95% CI): 2.03 (1.76 to 2.3)] and systemic vascular resistance (SVR) [SMD (95% CI): 1.20(0.94 to 1.45)] despite no change in LV end-diastolic volume reserve between groups. Conclusion: HFpEF patients have significantly reduced exercise capacity secondary to impaired central (decreased CI, SVI, HR reserve, and increased LV filling pressures without a change in LV diastolic reserve) and peripheral abnormalities (increased SVR and decreased a-VO 2 Diff).
Open label, non randomized, interventional study to evaluate response rate after induction therapy with docetaxel and cisplatin in unresectable locally advanced squamous cell carcinoma of head and neck (NCT02061631).
Authors: S. H. Manzoor Zaidi, Ahmed I. Masood, Syed Ijaz Hussain Shah, Irfan Hashemy
Journal: Journal of Clinical Oncology (2017)

e17513 Background: This single arm, multicenter, phase 2 study was conducted to evaluate overall response (OR) rate and safety of subjects treated with induction regimen docetaxel + cisplatin, followed by chemoradiotherapy (CRT), in patients with locally advanced squamous cell carcinoma of oral cavity (stage III or IV) without distant metastasis. Methods: Induction regimen consisted of docetaxel 75mg/m 2 and cisplatin 75mg/m 2 on day 1; cycles were repeated every 21 days for 3 cycles with supportive G-CSF treatment beginning at first cycle. CRT consisted of weekly cisplatin 30mg/m 2 for 4 weeks starting concomitantly with 60 Gy/30 fractions of conventional radiotherapy for 6 weeks. Primary and secondary efficacy criteria were OR rate at 3 weeks after cycle 3 and 8 weeks after last cycle of CRT respectively. Results: Three centers enrolled 35 patients. Primary efficacy endpoint: OR rate of evaluable patients (n = 27) was 88.9% (95% CI:71.9-96.2). Complete response (CR) was not achieved by any patients; partial response (PR) was achieved by 88.9% (24 of 27). From intent to treat (ITT) analysis OR rate was 68.6% (24 of 35). Secondary efficacy endpoint: OR rate of evaluable patients (n = 19) was 78.9% (95% CI:56.7-91.5) with CR and PR achieved by 2 (10.5%) and 13 (68.4%) patients respectively. Progressive disease (PD) was present in 4 patients. From ITT analysis CR rate was 5.7% (2 of 35) and OR rate was 42.9% (15 of 35). During induction most common hematological toxicity was leukopenia in 8 patients, with ≥Grade 3 leukopenia in 3 patients. Common non hematologic toxicities (all grades) were nausea, stomatitis and alopecia in 21, 18 and 18 patients respectively. During CRT most common adverse events were alopecia, stomatitis and nausea in 14, 13 and 13 patients respectively. Overall, leukopenia met seriousness criteria in 4 patients, and there was 1 case of febrile neutropenia. Overall, 7 patients died. Fatal events were not associated to investigational drugs. Conclusions: We observed an ITT response rate of 68.6% with docetaxel + cisplatin, suggestive of an active induction regimen with manageable safety profile. Clinical trial information: NCT02061631.
Clinical application of a novel CTC-chip to detect circulating tumor cells (CTCs) in malignant pleural mesothelioma (MPM).
Authors: Kazue Yoneda, Taiji Kuwata, Yasuhiro Chikaishi, Yoshinobu Ichiki, Takashi Ohnaga, Fumihiro Tanaka
Journal: Journal of Clinical Oncology (2018)

e24086 Background: The CellSearch, the only clinically approved platform to detect CTCs, provides no adequate sensitivity, especially in detection of CTCs with no or low expression of EpCAM such as MPM cells (Yoneda K. Ann Surg Oncol 2014). We developed a novel microfluidic platform (CTC-chip) to which any antibody for capturing CTCs can be conjugated (Oncol Rep 2017). In experimental studies, we further showed that the CTC-chip conjugated with an antibody against podoplanin, expressed on the surface of mesothelioma cells, enabled highly sensitive detection of mesothelioma cells spiked in the blood (AACR 2018). Methods: CTCs in the peripheral blood sampled from 25 MPM patients were quantitatively evaluated with the CTC-chip and with the CellSearch. Results: The CTC-chip showed a tremendously superior efficiency in detection of CTCs over CellSearch that detected only one CTC in one sample among the first 16 samples (p < 0.001, Table 1). One or more CTCs were detected with the CTC-chip in 16 (64%) of all 25 MPM patients. A receiver operating curve (ROC) analysis for prediction of advanced (or un-resectable) disease (stage IIIB or IV) showed that the CTC-chip provided a significant predictive capability with an area under the curve of 0.851 (p = 0.003). The sensitivity and specificity to predict advanced disease were 92.9% and 72.7% at the cut-off CTC-count value of “1”, and were 64.3% and 90.0% at the cut-off value of “2”. Overall survival (OS) was significantly poor in patients with higher CTC-count (2 or higher) than those with lower CTC-count (0 or 1) (median OS, 188 days versus 582 days; p = 0.030). Conclusions: The novel CTC-chip provides a superior performance in detection of CTCs, and may be useful in evaluation of tumor progression and in prediction of prognosis in MPM. Future validation studies are warranted. Table 1. Distribution of CTCs detected with CTC-chip and CellSearch. CTC-count (per 1ml for CTC-chip; per 7.5ml for CellSearch) Number of patients CTC-chip (n = 25) CellSearch (n = 16) 0 9 15 1 5 1 2 2 0 3 1 0 4 2 0 15 1 0 16 1 0 17 1 0 20 1 0 50 1 0 96 1 0
TCT-331 Secular Trends of Characteristics, Treatments, and Long-term Outcomes in Patients with Ostial or Mid-Shaft Left Main Coronary Artery Disease
Authors: Yong-Hoon Yoon, Sun Hack Lee, Sangwoo Park, Tae Oh Kim, Sang Yong Om, Minsoo Kim, Hanbit Park, Sang-Cheol Cho, Kyusup Lee, Osung Kwon, Euihong Ko, Do-yoon Kang, Pil Hyung Lee, Jung-Min Ahn, Soo-Jin Kang, Duk-Woo Park, Seung-Whan Lee, Young-Hak Kim, Cheol Whan Lee, Seong-Wook Park, Seung-Jung Park
Journal: Journal of the American College of Cardiology (2018)